Viveca Ritsinger1, Nawsad Saleh2, Bo Lagerqvist2, Anna Norhammar2. 1. From the Karolinska Institute, Department of Medicine, Cardiology Unit, Karolinska University Hospital, Stockholm, Sweden (V.R., N.S., A.N.); Department of Research and Development, Region Kronoberg, Sweden (V.R.); and Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden (B.L.). viveca.ritsinger@ki.se. 2. From the Karolinska Institute, Department of Medicine, Cardiology Unit, Karolinska University Hospital, Stockholm, Sweden (V.R., N.S., A.N.); Department of Research and Development, Region Kronoberg, Sweden (V.R.); and Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden (B.L.).
Abstract
BACKGROUND: Patients with diabetes mellitus have reduced longevity after acute coronary syndromes and revascularization. However, knowledge of the long-term complication rates and patterns from an everyday life setting is lacking. METHODS AND RESULTS: Consecutive patients undergoing percutaneous coronary intervention included in the Swedish Coronary Angiography Angioplasty Registry (SCAAR) between 2006 and 2010 and with no previous revascularization were prospectively followed up for combined cardiovascular events (first of all-cause mortality, myocardial infarction, stroke, and heart failure) until December 31, 2010. The mean follow-up period was 920 days (SD, 530 days). Differences in background and procedural characteristics were adjusted for in a multivariate Cox regression model. Of 58 891 patients, mean age 67 years, 19% had diabetes mellitus; 27% of them were on diet treatment, 33% on oral glucose lowering, and 40% on insulin treatment. At admission, cardiovascular risk factors, multiple coronary vessel, and left main stem disease were more frequent in patients with diabetes mellitus and their revascularization was less often complete. The adjusted risk for combined cardiovascular events was higher in patients on insulin (hazard ratio [95% confidence interval], 1.63 [1.55-1.72]), on oral treatment (1.23 [1.15-1.31]), and on diet alone (1.21 [1.12-1.29]) compared with patients without diabetes mellitus. Insulin-treated patients ran an increased risk of restenosis (1.54 [1.39-1.71]) and stent thrombosis (1.56 [1.25-1.96]). CONCLUSIONS: The prognosis after a first percutaneous coronary intervention is more severe in patients with diabetes mellitus, in particular, in patients treated with insulin, with higher rates of mortality, cardiovascular events, and stent thrombosis over the following 5 years.
BACKGROUND:Patients with diabetes mellitus have reduced longevity after acute coronary syndromes and revascularization. However, knowledge of the long-term complication rates and patterns from an everyday life setting is lacking. METHODS AND RESULTS: Consecutive patients undergoing percutaneous coronary intervention included in the Swedish Coronary Angiography Angioplasty Registry (SCAAR) between 2006 and 2010 and with no previous revascularization were prospectively followed up for combined cardiovascular events (first of all-cause mortality, myocardial infarction, stroke, and heart failure) until December 31, 2010. The mean follow-up period was 920 days (SD, 530 days). Differences in background and procedural characteristics were adjusted for in a multivariate Cox regression model. Of 58 891 patients, mean age 67 years, 19% had diabetes mellitus; 27% of them were on diet treatment, 33% on oral glucose lowering, and 40% on insulin treatment. At admission, cardiovascular risk factors, multiple coronary vessel, and left main stem disease were more frequent in patients with diabetes mellitus and their revascularization was less often complete. The adjusted risk for combined cardiovascular events was higher in patients on insulin (hazard ratio [95% confidence interval], 1.63 [1.55-1.72]), on oral treatment (1.23 [1.15-1.31]), and on diet alone (1.21 [1.12-1.29]) compared with patients without diabetes mellitus. Insulin-treated patients ran an increased risk of restenosis (1.54 [1.39-1.71]) and stent thrombosis (1.56 [1.25-1.96]). CONCLUSIONS: The prognosis after a first percutaneous coronary intervention is more severe in patients with diabetes mellitus, in particular, in patients treated with insulin, with higher rates of mortality, cardiovascular events, and stent thrombosis over the following 5 years.
Authors: Joo Myung Lee; Ki Hong Choi; Bon-Kwon Koo; Hakim-Moulay Dehbi; Joon-Hyung Doh; Chang-Wook Nam; Eun-Seok Shin; Christopher M Cook; Rasha Al-Lamee; Ricardo Petraco; Sayan Sen; Iqbal S Malik; Sukhjinder S Nijjer; Hernán Mejía-Rentería; Eduardo Alegria-Barrero; Ali Alghamdi; John Altman; Sérgio B Baptista; Ravinay Bhindi; Waldemar Bojara; Salvatore Brugaletta; Pedro Canas Silva; Carlo Di Mario; Andrejs Erglis; Robert T Gerber; Olaf Going; Tobias Härle; Farrel Hellig; Ciro Indolfi; Luc Janssens; Allen Jeremias; Rajesh K Kharbanda; Ahmed Khashaba; Yuetsu Kikuta; Florian Krackhardt; Mika Laine; Sam J Lehman; Hitoshi Matsuo; Martijin Meuwissen; Giampaolo Niccoli; Jan J Piek; Flavo Ribichini; Habib Samady; James Sapontis; Arnold H Seto; Murat Sezer; Andrew S P Sharp; Jasvindar Singh; Hiroaki Takashima; Suneel Talwar; Nobuhiro Tanaka; Kare Tang; Eric Van Belle; Niels van Royen; Hugo Vinhas; Christiaan J Vrints; Darren Walters; Hiroyoshi Yokoi; Bruce Samuels; Chris Buller; Manesh R Patel; Patrick Serruys; Javier Escaned; Justin E Davies Journal: JAMA Cardiol Date: 2019-09-01 Impact factor: 14.676
Authors: Jenny Ruedlinger; Yalena Prado; Tomás Zambrano; Nicolás Saavedra; Braulio Bobadilla; Marcelo Potthoff; Luis Pérez; Fernando Lanas; Luis A Salazar Journal: Biomed Res Int Date: 2017-07-13 Impact factor: 3.411
Authors: Thomas Nyström; Johan Bodegard; David Nathanson; Marcus Thuresson; Anna Norhammar; Jan W Eriksson Journal: Diabetes Obes Metab Date: 2017-03-16 Impact factor: 6.577
Authors: Marco Trevisan; Edouard L Fu; Karolina Szummer; Anna Norhammar; Pia Lundman; Christoph Wanner; Arvid Sjölander; Tomas Jernberg; Juan Jesus Carrero Journal: Eur Heart J Cardiovasc Pharmacother Date: 2021-03-15
Authors: T M Hommels; R S Hermanides; B Berta; E Fabris; G De Luca; E H Ploumen; C von Birgelen; E Kedhi Journal: Cardiovasc Diabetol Date: 2020-10-02 Impact factor: 9.951